Long-term Survival Benefit of Anti-PD-1 Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma
In September 2023, a study led by Professor Jun Zhu from Peking University Cancer Hospital and Institute was published in the prestigious international academic journal ——Signal Transduction and Targeted Therapy (IF=38.12). The title…